Search

Search Constraints

You searched for: Author/Creator Cardone, Claudia

Search Results

1. Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. (June 2021)

2. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. (October 2020)

3. Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis. (13th February 2018)

4. Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. Issue 4 (16th August 2019)

6. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer. Issue 9 (31st July 2019)

7. Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. (June 2020)